Short Wave Pharma is a biopharmaceutical company developing novel formulations of psilocybin and additional APIs, along with customized delivery methods, for patients living with mental health disorders, neurodegenerative diseases, chronic pain, and any other medical conditions for which psilocybin is known to have a positive effect. Short Wave Pharma has begun preclinical studies related to its product for anorexia nervosa. The company’s future programs include the development of novel formulations and delivery approaches for chronic pain and neurodegenerative diseases.